MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of$ 0.14. This compares to loss of $0.10 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 35.71%. A quarter ago, it was expected that this company would post a loss of$ 0.14 per share when it actually produced a loss of $0.09, delivering a surprise of 35.71%. Over the last four quarters, the company has surpassed ...